Beyond castration and chemotherapy: Novel approaches to targeting androgen-driven pathways
Keywords: MDV3100; Abiraterone; Phase III; Castrate-resistant prostate cancer; Hormone-refractory prostate cancer; Prostate cancer; Targeted therapy; Novel therapy; Biologic therapy;